News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Immune-Onc Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Business
What You Need to Know About Immune-Onc Therapeutics
Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.
December 13, 2017
·
5 min read
·
Mark Terry
Bio NC
Top 20 Life Science Startups to Watch in 2018
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
December 4, 2017
·
9 min read
·
Mark Terry
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting
December 9, 2024
·
7 min read
FDA
Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020
November 10, 2020
·
6 min read
Biotech Bay
Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020
November 9, 2020
·
4 min read
Drug Development
Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia
September 16, 2020
·
4 min read
Biotech Bay
Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4
August 4, 2020
·
4 min read
FDA
Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance
May 29, 2020
·
3 min read
Business
Company Profile for Immune-Onc Therapeutics, Inc.
November 21, 2019
·
1 min read
Business
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions
November 19, 2019
·
8 min read
Business
Immune-Onc Therapeutics Announces Key Executive Appointments and Series B Funding
September 18, 2018
·
5 min read
Biotech Bay
Immune-Onc Therapeutics Awarded “Buzz of BIO”
October 12, 2017
·
2 min read